Orphazyme strengthens balance sheet with €9m financing from Kreos Capital

By 28/08/2019June 4th, 2021No Comments

Anders Fink Vadsholt, CFO of Orphazyme said, “Engaging in this loan facility diversifies our financing strategy and allows us, with only limited dilution, to bolster our cash position as we move closer to significant value inflection points, including the anticipated filing of arimoclomol for NPC in the US and Europe during H1 2020.”

Aris Constantinides​, General Partner at Kreos, commented, “This is an important time for Orphazyme as the company prepares to file its lead program with regulatory authorities in the US and Europe. We are very pleased to support Orphazyme in its mission to bring innovative new medicines to patients with rare diseases.”